Nathaniel Brown

Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis

Management of hepatitis B

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel

Role of melanocortinergic neurons in feeding and the agouti obesity syndrome

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

Protein Kinase A and G Protein-coupled Receptor Kinase Phosphorylation Mediates β-1 Adrenergic Receptor Endocytosis through Different Pathways

Review article: hepatitis B and liver transplantation

Treatment predictors of a sustained virologic response in hepatitis B and C

Genetic analysis of immortalizing functions of Epstein–Barr virus in human B lymphocytes

Hepatitis B Virus Infection — Natural History and Clinical Consequences

Nucleoside Analog Inhibitors of Hepatitis C Virus Replication

In vitro selected Con1 subgenomic replicons resistant to 2′-C-Methyl-Cytidine or to R1479 show lack of cross resistance

Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis B

In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Virologic response and resistance to adefovir in patients with chronic hepatitis B

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B

Hepatitis flares and hepatitis B e antigen seroconversion: Implication in anti‐hepatitis B virus therapy¹

Evaluation of Chronic Hepatitis B Virus (HBV) Infection in Coinfected Patients Receiving Lamivudine as a Component of Anti-Human Immunodeficiency Virus Regimens

A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

Hepatitis B: Reflections on the current approach to antiviral therapy

Liver fibrosis – from bench to bedside

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides

Molecular diagnosis of viral hepatitis

Week 48 Resistance Surveillance in Two Phase 3 Clinical Studies of Adefovir Dipivoxil for Chronic Hepatitis B

Hepatitis B Virus Infection

Management of hepatitis B: 2000—Summary of a workshop

Long-term safety of lamivudine treatment in patients with chronic hepatitis B

Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C

A randomized controlled trial of lamivudine to treat acute hepatitis B

Antiviral drug-resistant HBV

Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #

Pathogenic roles for Epstein–Barr virus (EBV) gene products in EBV-associated proliferative disorders

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance

Hepatitis B virus infection

Chronic hepatitis B

Overdependence on degraded gist memory in Alzheimer's disease.

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B

Reshaping human antibodies for therapy

Mutations in Hepatitis B Dna Polymerase Associated With Resistance to Lamivudine Do Not Confer Resistance to Adefovir In Vitro

A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

The role of resistance in HCV treatment

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice

Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease

Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B

Hepatitis B vaccines

Long‐term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA†

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

Effect of virological response on post‐treatment durability of lamivudine‐induced HBeAg seroconversion

Natural and iatrogenic variation in hepatitis B virus

Treatment of chronic hepatitis B

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B

MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

Molecular and cellular mechanisms of liver fibrosis and its regression

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation

A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B

Viral hepatitis B

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection

Determinants for Membrane Association of the Hepatitis C Virus RNA-dependent RNA Polymerase

Skin Hygiene and Infection Prevention: More of the Same or Different Approaches?

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B

Chronic hepatitis B

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

Extended Lamivudine Treatment in Patients With Chronic Hepatitis B Enhances Hepatitis B E Antigen Seroconversion Rates: Results After 3 Years of Therapy

Hepatitis C Virus RNA-Dependent RNA Polymerase (NS5B Polymerase)

Ymdd Motif in Hepatitis B Virus Dna Polymerase Influences on Replication and Lamivudine Resistance: A Study By In Vitro Full–Length Viral Dna Transfection

Human mitochondrial RNA polymerase: Structure–function, mechanism and inhibition

Chronic hepatitis B: Update 2009 #

Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

Role of viral factors in the natural course and therapy of chronic hepatitis B

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti-HBc positivity in the donor population

Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B

Clinical Trial of Lamivudine in Children with Chronic Hepatitis B

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B

Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy

Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift.

Cyclic AMP- and Cyclic GMP-dependent Protein Kinases Differ in Their Regulation of Cyclic AMP Response Element-dependent Gene Transcription

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study

Hepatitis C Virus-Specific Directly Acting Antiviral Drugs

In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Determinants for Sustained Hbeag Response to Lamivudine Therapy

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

Efficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Bb

Hepatitis B virus infection

Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy

Outcome of Hepatitis B e Antigen–Negative Chronic Hepatitis B on Long-Term Nucleos(t)ide Analog Therapy Starting With Lamivudine *

A One-Year Trial of Lamivudine for Chronic Hepatitis B

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine‐resistant mutants

Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

Kaposi's Sarcoma–Associated Herpesvirus-Like DNA Sequences in AIDS-Related Body-Cavity–Based Lymphomas

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase

Degradation of the Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) by the Ubiquitin-Proteasome Pathway

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).

Replicative Senescence of Activated Human Hepatic Stellate Cells Is Accompanied by A Pronounced Inflammatory But Less Fibrogenic Phenotype

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

The Use of Antiseptics for Handwashing by Medical Personnel

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

Evolution of Hepatitis B Virus Polymerase Gene Mutations in Hepatitis B E Antigen-Negative Patients Receiving Lamivudine Therapy

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

Hepatocellular Carcinoma

Histological outcome during long-term lamivudine therapy

The way forward in HCV treatment — finding the right path

Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B

Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion

Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants

Chronic Hepatitis B: Current Testing Strategies

Entecavir therapy for lamivudine‐refractory chronic hepatitis B

Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

Sustained response after a 2‐year course of lamivudine treatment of hepatitis B e antigen‐negative chronic hepatitis B

Long-term therapy of chronic hepatitis B with lamivudine

Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells.

A Vector That Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus

Epstein-Barr Virus-Encoded Bcl-2 Homologue Functions as a Survival Factor in Wp-Restricted Burkitt Lymphoma Cell Line P3HR-1

A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus.

Precision of genotyping of Epstein-Barr virus by polymerase chain reaction using three gene loci (EBNA-2, EBNA-3C, and EBER): predominance of type A virus associated with Hodgkin's disease [published erratum appears in Blood 1993 Oct 1;82(7):2268]

A protective human monoclonal IgA antibody produced in vitro: Anti‐pneumococcal antibody engendered by Epstein‐Barr virus‐immortalized cell line

Hepatocellular Carcinoma

Reshaping Human Antibodies: Grafting an Antilysozyme Activity

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

Hepatitis B Virus Biology

The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation

Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma

A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q

Identification of Epstein-Barr nuclear antigen polypeptide in mouse and monkey cells after gene transfer with a cloned 2.9-kilobase-pair subfragment of the genome.

A Causal Link Between Handwashing and Risk of Infection? Examination of the Evidence

Identification of Virus-Encoded MicroRNAs

Ultrastructural analysis of hepatitis C virus particles

The Biology and Chemistry of Epstein-Barr Virus

Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems

Characterization of Immunoregulatory T Cells in EBV-Induced Infectious Mononucleosis by Monoclonal Antibodies

Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis

Life with 6000 Genes

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B

A deletion map of the human immunoglobulin heavy chain variable region.

Burkitt's Lymphoma

A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-α2b and Lamivudine with Lamivudine Alone

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective

Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6

Cellular Mechanisms of Tissue Fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis

Molecular cloning, expression, and gene localization of a fourth melanocortin receptor

Inhibition of Hepatitis B Virus Polymerase by Entecavir

Pneumocystis cariniiPneumonia and Mucosal Candidiasis in Previously Healthy Homosexual Men

Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage

Epstein-Barr Virus (EBV) Induced Polyclonal and Monoclonal B-Cell Lymphoproliferative Diseases Occurring after Renal Transplantation

Review HCV Antiviral Resistance: The Impact of in vitro Studies on the Development of Antiviral Agents Targeting the Viral NS5B Polymerase

HBV genotype B is associated with better response to interferon therapy in HBeAg( + ) chronic hepatitis than genotype C

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir

Molecular cloning of a novel melanocortin receptor.

Effects of Recombinant Agouti-Signaling Protein on Melanocortin Action

Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein

DNA sequence and expression of the B95-8 Epstein—Barr virus genome

Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors

RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase

Structure of defective DNA molecules in Epstein-Barr virus preparations from P3HR-1 cells

Executive Functions Deficit in Parkinson’s Disease With Amnestic Mild Cognitive Impairment

Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids

LIVER TRANSPLANTATION FOR CHRONIC VIRAL HEPATITIS

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

Future Therapies for Hepatitis C

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient

Major EB virus-specific cytoplasmic transcripts in a cellular clone of the HR-1 burkitt lymphoma line during latency and after induction of viral replicative cycle by phorbol esters

No Benefit to Continue Lamivudine Therapy after Emergence of Ymdd Mutations

Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.

The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus.

Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.

Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T ₁ -weighted MRI

Human lymphocyte Hybridomas and Monoclonal Antibodies

Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection

In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil

Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders

2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B

Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B

Multicenter Study of Lamivudine Therapy for Hepatitis B After Liver Transplantation

Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection

Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States

Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with Lamivudine

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine

A Multicenter United States—Canadian Trial to Assess Lamivudine Monotherapy Before and After Liver Transplantation for Chronic Hepatitis B

Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy

624 Absence of effect of pegylated interferon alpha-2b on the pharmacokinetics of valopicitabine (NM283) in patients with chronic hepatitis C

Durable HBeAg and HBsAg seroconversions after lamivudine for chronic hepatitis B (CHB)

52 A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis

Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients.

Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein Barr virus.

[6] VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO PEGIFN/RBV: ONE-YEAR RESULTS

514 HBV resistance determination from the telbivudine globe registration trial

A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B

Infectious Mononucleosis: A Polyclonal B Cell Transformation in Vivo

96 First clinical results for a novel antiviral treatment for hepatitis C: A phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283

Diffuse Polyclonal B-Cell Lymphoma during Primary Infection with Epstein–Barr Virus

B-cell lymphoproliferation and lymphomagenesis are associated with clonotypic intracellular terminal regions of the Epstein-Barr virus

Health care costs associated with chronic hepatitis B

Clonal origins of lymphoproliferative disease induced by Epstein-Barr virus

Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis be-antigen (HBeAg) seroconversion

New Epstein–Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma

Gram-Negative Sepsis in Neonates: A Nursery Outbreak Due to Hand Carriage of Citrobacter diversus

51 Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients

Induction of alkaline phosphatase in mouse L cells by overexpression of the catalytic subunit of cAMP-dependent protein kinase.

Immunoglobulin JH, C mu, and C gamma gene rearrangements in human B lymphocytes clonally transformed by Epstein-Barr virus.